BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
cell-cell adhesion
,
Ischemia
,
Prostate
,
Personalized medicine
,
Ciprofibrate
,
TGFB1
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
cdk9 protein, human
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
Colon cancer cells (HCT116) with CDK9, CDK12 or CDK13 knockdown
Breast cancer MCF7 cells treated with AZD4573 CDK9 inhibitor
T cell acute lymphoblastic leukemia MOLT4 cells treated with cyclin-dependent kinase inhibitors
Acute myeloid leukemia HL60 cells treated with JSH-009 compound
B cell lymphoma VAL and OCI-LY3 cells treated with CDK-9 inhibitor AZ5576 compound
Explore Curated Studies Results
Literature
Most Relevant Literature
Mechanistic Insights into a CDK9 Inhibitor Via Orthogonal Proteomics Methods.
O-GlcNAc transferase maintains metabolic homeostasis in response to CDK9 inhibition.
CDK9 is up-regulated and associated with prognosis in patients with papillary thyroid carcinoma.
Targeting AraC-Resistant Acute Myeloid Leukemia by Dual Inhibition of CDK9 and Bcl-2: A Systematic R…
Selective CDK9 degradation using a proteolysis-targeting chimera (PROTAC) strategy.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression
Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial…
Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or G…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ